Seizure: European Journal of Epilepsy
Volume 19, Issue 6 , Pages 356-358 , July 2010

Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy

  • Sang-Ahm Lee

      Affiliations

    • Department of Neurology, University of Ulsan, Seoul, Republic of Korea
    • ,
  • Kyoung Heo

      Affiliations

    • Department of Neurology, Yonsei University, Seoul, Republic of Korea
    • ,
  • Won-Joo Kim

      Affiliations

    • Department of Neurology, Yonsei University, Seoul, Republic of Korea
    • ,
  • Hong-Ki Song

      Affiliations

    • Department of Neurology, Hallym Institute of Epilepsy Research, Seoul, Republic of Korea
    • ,
  • Sung-Eun Kim

      Affiliations

    • Department of Neurology, Inje University, Pusan, Republic of Korea
    • ,
  • Sang-Ho Kim

      Affiliations

    • Department of Neurology, Dong-A University, Pusan, Republic of Korea
    • ,
  • Soon-Kee No

      Affiliations

    • Department of Neurology, Bong-Seng Memorial Hospital, Pusan, Republic of Korea
    • ,
  • Byung-In Lee

      Affiliations

    • Department of Neurology, Yonsei University, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Department of Neurology, Yonsei University College of Medicine, Severance Hospital, 134 Sinchon-dong, Seodaemun-gu, Seoul 120-752, Republic of Korea. Tel.: +82 2 2228 1600.

Received 14 January 2010 ,Revised 14 April 2010 ,Accepted 7 May 2010.

References 

  1. Schmidt D, Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav. 2000;1:396–405
  2. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42:1023–1042
  3. Barcs G, Walker E, Elger CE, Scaramelli A, Stefan H, Sturm Y, et al. Oxcarbazepine: placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597–1607
  4. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs. 2001;15:137–163
  5. Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis ML, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand. 2001;104:167–170
  6. Schachter SC, Vazquez B, Fisher RS, Laxer KD, Montouris GD, Combs-Cantrell DT, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999;52:732–737
  7. Beydoun A, Sachdeo RC, Rosenfeld WE, Krauss GL, Sessler N, Mesenbrink P, et al. Oxcarbazepine monotherapy for partial-onset seizures. Neurology. 2000;54:2245–2251
  8. Albani F, Grassi B, Ferrara R, Turrini R, Baruzzi A. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure. 2004;13:254–263
  9. Albani F, Bisulli F, Bartezaghi M, Turrini R, Baruzzi A the SECONDO Study Group. Multicentre observational study evaluating immediate and progressive switching from carbamazepine to oxcarbazepine in patients with epilepsy. Funct Neurol. 2007;22:111–115
  10. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87:224–227
  11. Smith PE. Clinical recommendations for oxcarbazepine. Seizure. 2001;10:87–91

PII: S1059-1311(10)00106-8

doi: 10.1016/j.seizure.2010.05.002

Seizure: European Journal of Epilepsy
Volume 19, Issue 6 , Pages 356-358 , July 2010

Article Tools